{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:59:55Z","timestamp":1790398795176,"version":"4.1.0"},"reference-count":26,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2026]]},"DOI":"10.5582\/ddt.2026.01067","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:10:56Z","timestamp":1790287856000},"source":"Crossref","is-referenced-by-count":0,"title":["Daraxonrasib: The first-in-class RAS(ON) multi-selective inhibitor approved for treatment of metastatic pancreatic adenocarcinoma"],"prefix":"10.5582","author":[{"given":"Yueyi","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Park W, Chawla A, O&apos;Reilly EM. Pancreatic cancer: A review. JAMA. 2021; 326:851-862.","DOI":"10.1001\/jama.2021.13027"},{"key":"2","unstructured":"2. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: Pancreatic cancer. National Cancer Institute. <i>https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html<\/i> (accessed September 15, 2026)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026; 76:e70090.","DOI":"10.3322\/caac.70090"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024; 4:47-53.","DOI":"10.1016\/j.jncc.2024.01.006"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tai D, Conroy T, Lee JJX, <i>et al<\/i>. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. ESMO Open. 2025; 10:105826.","DOI":"10.1016\/j.esmoop.2025.105826"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wainberg ZA, Melisi D, Macarulla T, <i>et al.<\/i> NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial. Lancet. 2023; 402:1272-1281.","DOI":"10.1016\/S0140-6736(23)01366-1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Von Hoff DD, Ervin T, Arena FP, <i>et al<\/i>. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369:1691-1703.","DOI":"10.1056\/NEJMoa1304369"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Conroy T, Desseigne F, Ychou M, <i>et al.<\/i> FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364:1817-1825.","DOI":"10.1056\/NEJMoa1011923"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wang-Gillam A, Li CP, Bodoky G, <i>et al.<\/i> Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Lancet. 2016; 387:545-557.","DOI":"10.1016\/S0140-6736(15)00986-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sohal DPS, Kennedy EB, Cinar P, <i>et al.<\/i> Metastatic pancreatic cancer: ASCO Guideline Update. J Clin Oncol. 2020; 38:3217-3230.","DOI":"10.1200\/JCO.20.01364"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Gorner M, Molle M, Greten TF, Lakner V, Bischoff S, Sinn M, Dorken B, Pelzer U. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: Outcomes from the CONKO-003 trial. J Clin Oncol. 2014; 32:2423-2429.","DOI":"10.1200\/JCO.2013.53.6995"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, Zalewski P, Do T, Cano P, Lam WYH, Dowden S, Grassin H, Stewart J, Moore M. PANCREOX: A randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016; 34:3914-3920.","DOI":"10.1200\/JCO.2016.68.5776"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. de Jesus VHF, Mathias-Machado MC, de Farias JPF, Aruquipa MPS, Jacome AA, Peixoto RD. Targeting KRAS in pancreatic ductal adenocarcinoma: The long road to cure. Cancers (Basel). 2023; 15:5015.","DOI":"10.3390\/cancers15205015"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nakajima EC, Drezner N, Li X, <i>et al<\/i>. FDA Approval Summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res. 2022; 28:1482-1486.","DOI":"10.1158\/1078-0432.CCR-21-3074"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Mahran R, Kapp JN, Valtonen S, Champagne A, Ning J, Gillette W, Stephen AG, Hao F, Pluckthun A, Harma H, Pantsar T, Kopra K. Beyond KRAS(G12C): Biochemical and computational characterization of sotorasib and adagrasib binding specificity and the critical role of H95 and Y96. ACS Chem Biol. 2024; 19:2152-2164.","DOI":"10.1021\/acschembio.4c00315"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Strickler JH, Satake H, George TJ, <i>et al<\/i>. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med. 2023; 388:33-43.","DOI":"10.1056\/NEJMoa2208470"},{"key":"17","unstructured":"17. US Food and Drug Administration. FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer. <i>https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer<\/i> (accessed September 10, 2026)."},{"key":"18","unstructured":"18. RASONQUE (daraxonrasib) tablets, for oral use. <i>https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/220910Orig1s000lbl.pdf<\/i> (Accessed September 10, 2026)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Jiang J, Jiang L, Maldonato BJ, <i>et al.<\/i> Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2024; 14:994-1017.","DOI":"10.1158\/2159-8290.CD-24-0027"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. O&apos;Reilly EM, Wainberg ZA, Hendifar AE, <i>et al.<\/i> Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. 2026; 395:325-337.","DOI":"10.1056\/NEJMoa2605555"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Wolpin BM, Wainberg ZA, Hendifar A, <i>et al<\/i>. Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study. J Clin Oncol. 2026; 44(Number 17_suppl). DOI: 10.1200\/JCO.2026.44.17_suppl.LBA5.","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA5"},{"key":"22","unstructured":"22. ClinicalTrials.gov. Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (RASolute 303). NCT07491445. <i>https:\/\/clinicaltrials.gov\/study\/NCT07491445<\/i> (Accessed September 12, 2026)."},{"key":"23","unstructured":"23. ClinicalTrials.gov. Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304). NCT07252232. <i>https:\/\/clinicaltrials.gov\/study\/NCT07252232<\/i> (Accessed September 12, 2026)."},{"key":"24","unstructured":"24. ClinicalTrials.gov. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301). NCT06881784. <i>https:\/\/clinicaltrials.gov\/study\/NCT06881784<\/i> (Accessed September 12, 2026)."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sang B, Ye LF, Fu Z, <i>et al<\/i>. Disrupted molecular glue complex drives RAS inhibitor resistance. Cell. 2026; 189:2918\u20132933 e2917.","DOI":"10.1016\/j.cell.2026.03.031"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Aronchik I, Kar S, Zhuang Y, <i>et al<\/i>. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Nat Med. 2026; 32:2865-2877.","DOI":"10.1038\/s41591-026-04537-w"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/advpub\/0\/advpub_2026.01067\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:29:54Z","timestamp":1790396994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/advpub\/0\/advpub_2026.01067\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":26,"URL":"https:\/\/doi.org\/10.5582\/ddt.2026.01067","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2026.01067"}}